Global Glycobiology Market is valued approximately at USD 1.04 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 14.64 % over the forecast period 2020-2027. Glycobiology is the science of saccharides (sugar chains or glycans) formation, biosynthesis, and biology. Glycobiology is the science of whole biology and includes the structure and function of carbohydrate-containing molecules (sugar and saccharides) also known as glycans. Key driving forces of the market includes increase in funding for proteomics and glycomics studies, increase in investment for research and development and technological advancements in glycomics instrumentation. Additionally, advancement of biotechnology and proteomics in the R&D and pharmaceutical industry the demand is projected to create significant growth opportunity in the market over the forecast period. However, stringent regulatory frameworks and high degree of consolidation in the market is expected to create significant barrier in the market over the forecast period. Apart from this, the key players of global Glycobiology market have adopted various strategies to gain competitive advantage including product launch, mergers and acquisition, partnerships and agreements, investment, funding and others. For instance, Agilent Technologies (US) launched Infinity Lab LC / MSD iQ System in June 2019. In June 2018, Thermo Fisher Scientific (US) had introduced UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer. In 2018, Shimadzu Corp. partnered with PREMIER Biosoft, a multinational bioinformatics solutions firm, with the goal of launching its LCMS-9030 Quadrupole Time of Flight (Q-TOF) mass spectrometry system for advance glycomics and lipidomics data processing.

The regional analysis of global Glycobiology market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the presence of key pharmaceutical and biopharmaceutical companies in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as evolving pharmaceutical and biopharmaceutical industries, investments by Contract Research Organizations (CROs), would create lucrative growth prospects for the Glycobiology market across Asia-Pacific region.

Major market player included in this report are:
Merck KGaA
Agilent Technologies
Thermo Fisher Scientific
New England Biolabs
Shimadzu Corporation
Takara Bio
Waters Corporation
Asparia Glycomics S.L.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Other Enzymes
Reagents & Chemicals

By Application:
Drug Discovery & Development
Disease Diagnostics
Other Applications

By End-user:
Academic Research Institutes
Pharmaceutical and Biotechnology Companies
Clinical Laboratories

By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Glycobiology Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers